Following the publication of the original article [1], it was noted that due to a typesetting error the Figs. 1 and 2 were not complete. In addition, Fig. 1B should be changed to Fig. 1b, and Fig. 4w should be corrected to Fig. 4e in the main text of the article.
Fig. 1
SNCG is overexpressed in EOC tissue and correlated with poor prognosis in patients with HGSOC. a IHC staining showed SNCG expression in the normal ovary, fallopian tube tissues, benign tumor, and borderline tumor (original magnification, × 200). b Representative images of IHC staining of SNCG expression in different pathological types of EOC tissues (original magnification, upper× 200, lower× 400). c Kaplan-Meier analysis was performed for EOC patients to analyze the association between SNCG expression and survival outcome (OS and PFS). d In the HGSOC cohort, Kaplan-Meier analysis indicated the correlation of SNCG overexpression with OS (upper) and PFS (lower). By multivariate Cox regression analysis (Forest plot), results showed that SNCG overexpression was an independent prognostic factor
Fig. 2
SNCG accelerates ovarian cancer cell proliferation, facilitates cell migration and invasion in vitro. a Western blot analysis of SNCG expression in different ovarian cancer cell lines. b The transfection efficiency was confirmed by Western blotting and qRT-PCR in SKOV3, HO-8901 PM, and OVCAR3 cells. c The MTT assay was used to detect ovarian cancer cell viability. d A soft agar assay was used to examine the proliferation of ovarian cancer cells. e Cell migration and invasion capabilities were determined using transwell assays (original magnification, × 200). f and g SKOV3 and HO-8910 PM cell transfectants were plated on FN and stained for SNCG, phalloidin, and nuclear. Moreover, cells were stained for Vimentin, MMP9, and F-actin. The individual or merged images visualized by a laser scanning confocal microscope (original magnification, × 1000). ▲, P < 0.05. *, P < 0.001. Ctrl: control; Ove: overexpression; Scr: scramble; sh1: small hairpin RNA 1; sh2: small hairpin RNA 2; sh3: small hairpin RNA 3
×
×
In the section “SNCG is overexpressed in EOC tissue and correlated with poor prognosis in patients with HGSOC”, (p = 0.055, Fig. 1c) should be corrected to (p = 0.058, Fig. 1c).
The correct figures have been included in this correction, and the original article has been corrected.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.
Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.
Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.
Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
